PMID- 38400133
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 12
IP  - 2
DP  - 2024 Jan 31
TI  - Incidence and Nature of Short-Term Adverse Events following COVID-19 Second 
      Boosters: Insights from Taiwan's Universal Vaccination Strategy.
LID - 10.3390/vaccines12020149 [doi]
LID - 149
AB  - This study evaluates the incidence and characteristics of adverse events (AEs) 
      following the second COVID-19 booster dose, leveraging Taiwan's distinctive 
      approach of extending booster vaccinations to all citizens, unlike the targeted 
      high-risk group strategies in other countries. Utilizing data from Taipei 
      Veterans General Hospital's Vaccine Adverse Event Reporting System (VAERS) from 
      27 October 2022 to 19 January 2023, this research examines AEs in 441 out of 1711 
      booster recipients, considering factors like age, vaccine brands, and booster 
      combinations. The findings revealed incidence rates (IRs) of 25.6% (95% CI: 
      21.1-30.8) after the first booster and 24.9% (95% CI: 20.5-30.0) after the 
      second, mostly non-serious, with those having AEs post-first booster being five 
      times more likely to report them again (incidence rate ratio, 5.02, p < 0.001). 
      Significantly, switching from the mRNA1273 vaccine to another brand reduced AE 
      risk by 18%. This study underscores that AEs are more repetitive than cumulative 
      with additional booster doses, advocating for personalized vaccination strategies 
      based on individual medical histories and previous vaccine reactions. These 
      insights are valuable for healthcare providers in discussing potential AEs with 
      patients, thereby improving vaccine compliance and public trust, and for 
      policymakers in planning future booster vaccination strategies.
FAU - Lin, Ching-Hao
AU  - Lin CH
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, 
      Taiwan.
FAU - Chen, Tsung-An
AU  - Chen TA
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, 
      Taiwan.
FAU - Chiang, Pin-Hsuan
AU  - Chiang PH
AD  - Big Data Center, Taipei Veterans General Hospital, Taipei 112, Taiwan.
FAU - Hsieh, Ai-Ru
AU  - Hsieh AR
AUID- ORCID: 0000-0003-3900-9101
AD  - Department of Statistics, Tamkang University, New Taipei City 251, Taiwan.
FAU - Wu, Bih-Ju
AU  - Wu BJ
AD  - Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan.
FAU - Chen, Po-Yu
AU  - Chen PY
AD  - Department of Family Medicine, Cheng Hsin General Hospital, Taipei 112, Taiwan.
FAU - Lin, Kuan-Chen
AU  - Lin KC
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, 
      Taiwan.
FAU - Tsai, Zih-Syun
AU  - Tsai ZS
AD  - Big Data Center, Taipei Veterans General Hospital, Taipei 112, Taiwan.
FAU - Lin, Ming-Hwai
AU  - Lin MH
AUID- ORCID: 0000-0001-6825-6692
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, 
      Taiwan.
AD  - School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
FAU - Chen, Tzeng-Ji
AU  - Chen TJ
AUID- ORCID: 0000-0002-8350-0232
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, 
      Taiwan.
AD  - School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Hsinchu Branch, 
      Hsinchu 31064, Taiwan.
FAU - Chen, Yu-Chun
AU  - Chen YC
AUID- ORCID: 0000-0002-4124-1949
AD  - Department of Family Medicine, Taipei Veterans General Hospital, Taipei 112, 
      Taiwan.
AD  - Big Data Center, Taipei Veterans General Hospital, Taipei 112, Taiwan.
AD  - School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
LA  - eng
GR  - V111E-002-1, V112E-001-1, V113E-002- 408/Taipei Veterans General Hospital/
PT  - Journal Article
DEP - 20240131
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10892656
OTO - NOTNLM
OT  - COVID-19 booster vaccination
OT  - Taiwan's vaccination program
OT  - adverse events
OT  - immunization strategies
OT  - mRNA vaccines
OT  - pharmacovigilance
OT  - real-world evidence
OT  - vaccine safety
COIS- The authors declare no conflicts of interest.
EDAT- 2024/02/24 11:43
MHDA- 2024/02/24 11:44
PMCR- 2024/01/31
CRDT- 2024/02/24 01:23
PHST- 2024/01/01 00:00 [received]
PHST- 2024/01/27 00:00 [revised]
PHST- 2024/01/28 00:00 [accepted]
PHST- 2024/02/24 11:44 [medline]
PHST- 2024/02/24 11:43 [pubmed]
PHST- 2024/02/24 01:23 [entrez]
PHST- 2024/01/31 00:00 [pmc-release]
AID - vaccines12020149 [pii]
AID - vaccines-12-00149 [pii]
AID - 10.3390/vaccines12020149 [doi]
PST - epublish
SO  - Vaccines (Basel). 2024 Jan 31;12(2):149. doi: 10.3390/vaccines12020149.